Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Retatrutide

Also known as: LY3437943

MetabolicClinical trialsPubMed records: 30count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O Retatrutide é um agonista triplo dos receptores GLP-1, GIP e Glucagon, desenvolvido pela Eli Lilly. Representa a próxima geração em tratamento metabólico, com ~24% de perda de peso em ensaios de Fase II — o maior resultado já registrado para qualquer farmacoterapia para obesidade. Original in PT-BR

Retatrutide is catalogued under Metabolic. 28 Eagle articles in this library reference this compound.

Category
Metabolic
Research stage
Clinical trials — Ensaios Clínicos (Fase III — Eli Lilly) Original in PT-BR
PubMed records
30 (count from PubMed, not curated)
Eagle articles on this compound
28 Eagle articles

Mechanism

Agonista triplo GLP-1/GIP/Glucagon — máximo efeito metabólico Original in PT-BR

O Retatrutide é um peptídeo sintético que ativa simultaneamente três receptores: GLP-1R (reduz apetite, melhora insulina), GIPR (potencializa efeitos incretínicos, modula metabolismo adiposo) e GCGR (receptor de glucagon — aumenta gasto energético, termogênese hepática e lipólise). Esta ativação tripla produz efeitos superiores a qualquer agonista único ou duplo: a saciedade mediada pelo GLP-1/GIP é complementada pelo aumento do gasto energético via glucagon. O componente glucagon também promove lipólise hepática direta, reduzindo esteatose (fígado gorduroso). Em Fase II, pacientes perderam até 24.2% do peso corporal em 48 semanas. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
2381089-83-2
Molecular formula
Não divulgada (proprietária Eli Lilly) Original in PT-BR
Molecular weight
~4500 g/mol (estimado) Original in PT-BR
Sequence
Proprietária (Eli Lilly) Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Solução aquosa tamponada Original in PT-BR
Stability
Dados proprietários Original in PT-BR
Half-life
~6 dias Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
2-4 semanas (saciedade), 8-12 semanas (perda de peso máxima) Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

80/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Perda de peso de 24.2% em 48 semanas na dose máxima — recorde para farmacoterapia Original in PT-BR

    PMID: 37385268Year: 2023Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Redução significativa de gordura hepática — potencial tratamento para NAFLD/NASH Original in PT-BR

    PMID: 37840095Year: 2023Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Náusea (dose-dependente)
  • Diarreia
  • Vômitos
  • Constipação
  • Diminuição do apetite

Serious

  • Dados de longo prazo ainda não disponíveis
  • Risco teórico de pancreatite (classe)
  • Risco teórico de carcinoma medular de tireoide (classe)

Contraindications

  • MEN2
  • Histórico de carcinoma medular de tireoide
  • Pancreatite
  • Gravidez/amamentação

Warnings

  • Composto em Fase III — não aprovado
  • Escalonamento gradual obrigatório
  • Perda de massa magra possível sem exercício

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Retatrutide.

Lab tests named in the source

  • HbA1c
  • Glicemia de jejum
  • Perfil lipídico
  • Amilase/lipase
  • TSH
  • Função hepática
  • Esteatose hepática (US abdômen)

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Inicial
0.5mg SC/semana Original in PT-BR
Dose Máxima
12mg SC/semana (Fase II) Original in PT-BR
Frequência
1x por semana Original in PT-BR
Timing
Qualquer horário Original in PT-BR
Ciclo
Contínuo (sob supervisão) Original in PT-BR

Vial sizes: 10mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Compatible

Caution

Avoid

Related

View all (28)

← Back to knowledge area